Role of ADAMTS13 deficiency in development of renal microcirculatory tromboses, not associated with thrombotic, thrombocytopenic purpura


Cite item

Full Text

Abstract

Aim. Assessment of activity of ADAMTS13, von Willebrand factor and thrombocytes in patients with thrombophilic states and kidney diseases.
Methods. 20 patients with thrombophilia (genetically based and antiphospholipid syndrome) and kidney diseases (lupus nephritis, chronic glomerulonephritis) with morphological signs of renal thrombotic microngiopathy were included into the study. In all patients serum activity of ADAMTS13 and von Willebrand factor was determined.
Results. Serum activity of ADAMTS13 below the reference (<93%) values (56-92%) was found in 8 (40%) of patients. Serum activity of ADAMTS13 inversly correlated with level of von Willebrand factor (r= -0,3, р<0,05) and directly correlated with thrombocytes blood count (r= 0,57, р<0,01). The most low levels of serum activity of ADAMTS13 were seen in 2 patients with morphological signs of renal acute thrombotic microangiopathy.
Conclusion. Deterioration of ADAMTS13 - von Willebrand factor - thrombocytes cascade can be interpreted as universal mechanism of thombus formation in renal microcirculation.

References

  1. Moake JL, Rudy CK, Troll JH et al. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982;307:1432-1435
  2. Moake JL, Turner NA, Stathopoulos NA et al. Involvement of large plasma von Willebrand factor (VWF) multimers and unusually large VWF forms derived from endothelial cells in shear stress induced platelet aggregation. J Clin Invest 1986;78(6):1456-1461
  3. Furlan M, RoblesR, Lämmle B et al.. Deficit ADAMTS13, activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997; 89(9):3097-3103.
  4. Tsai HM, Lian EC Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura N Engl J Med 1998;339(22):1585-1494.
  5. Levy GG, Nichols WC, Lian EC et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature2001;413(6855):488-494.
  6. Furlan M, Robles R, Solenthaler M, Lämmle B. Acquired deficiency of von Willebrand factor - cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood 1998;91(8):2839-2846.
  7. Feng Yu, Ying Tan, Ming-Hui Zhao Lupus nephritis combined with renal injury due to thrombotic thrombocytopenic purpura-haemolytic uraemic syndrome. Nephrol Dial Transplant 2010; 25:145-152.
  8. Kwok SK, Ju JH, Cho CS et al. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: risk factors and clinical outcome: a single centre study. Lupus 2009;18:16-21.
  9. Dong JF, Moake JL, Nolasco L et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002;100(12):4033-4039.
  10. Bernardo A, Ball C, Nolasco L et al. Platelets adhered to endothelial cell-bound ultra-large von Willebrand factor strings support leucocyte tethering and rolling under high shear stress. J Thromb Haemost 2005; 3(3):562-570.
  11. Moake JL. Thrombotic microangiopathies. N Engl J Med.2002; 347:589-600.
  12. Bianchi V, Robles R, Alberio L, et al. Von Willebrand cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 2002; 100(2):710-713.
  13. Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 2008;112:11-18.
  14. Fuchigami S, Kaikita K, Soejima K et al. Changes in plasma von Willebrand factor-cleaving protease(ADAMTS13)levels in patients with unstable angina Thromb Res 2008;122(5):618-623,
  15. Bongers TN, de Bruijne EL, Dippel DW et al. Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients. Atherosclerosis 2009;207(1):250-254.
  16. Bongers TN, de Maat MP, van Goor ML et al. High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation and genetic variability. Stroke 2006; 37(11):2672-2677.
  17. Uemura M, Fujimura Y, Matsuyama T et al. Potential role of ADAMTS13 in the progression of alcoholic hepatitis. Curr Drug Abuse Rev 2008; 1(2):188-196.
  18. Morioka C, Uemura M, Matsuyama T et al. Plasma ADAMTS13 activity parallels the APACHE II score, reflecting an early prognostic indicator for patients with severe acute pancreatitis. Scand J Gastroenterol 2008; 43(11):1387-1396.
  19. Yonq Keun Kim, Jonqwook Lee, Kyunq-A Lee et al. Clinical Significance of von Willebrand factor-cleaving protease (ADAMTS13) deficiency in patients with sepsis-induced disseminated intravascular coagulation. Infectional Chemotherapy 2009;.41 (2): 78-81
  20. Ono T, Mimuro J, Madoiwa S et al. Severe secondary deficiency of von Willebrand factor-cleaving protease(ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood 2006;107:528-534.
  21. Kremer Hovinga JA, Zeerleder S, Kessler P et al. ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock. J Thromb Haemost 2007;5(11):2284-2290.
  22. Mannucci PM, Canciani MT, Forza I et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor.Blood 2001;98:2730-2735.
  23. Franchini M, Montagnana M, Targher G, Lippi G. Reduced von Willebrand factor-cleaving protease levels in secondary thrombotic microangiopathies and other disease. Semin Thromb Hemost 2007;33(8):787-797.
  24. Van den Born BH, van der Hoeven NV, Groot E et al. Association between thrombotic microangiopathy and reduced ADAMTS-13 activity in malignant hypertension. Hypertension 2008; 51:862-866.
  25. Austin SK, Starke RD, Lawrie AS et al. The VWF/ ADAMTS13 axis in the antiphospholipid syndrome: ADAMTS13 antibodies and ADAMTS13 dysfunction. Br J Haematol 2008;141:536-544.
  26. Carvalho JF, Freitas CAEW, Lima IVS et al. Primary antiphospholipid syndrome with thrombotic thrombocytopenic purpura: a very unusual association. Lupus 2009;18:841-844
  27. Lu G, Shen L, Wang Z et al. Significance of plasma von Willebrand factor level and von Willebrand factor -cleaving protease activity in patient with chronic renal disease. Chin Med J 2008;121(2):133-136.
  28. Raife TJ, Lentz SR, Atkinson BS et al. Factor V Leiden: a genetic risk factor for thrombotic microangiopathy in patients with normal von Willebrand factor-cleaving protease activity. Blood 2002; 99: 437-442.
  29. Gong R, Liu Z, Chen Z, Li L. Genetic variations in plasminogen activator inhibitor-1 gene and beta fibrinogen gene associated with glomerular microthrombosis in lupus nephritis and the gene dosage effect. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2002;19: 1-5
  30. Sucker C., Kurschat C., Farokhzad F. et al. The TT Genotype of the C677T Polymorphism in the Methylentetrahydrofolate Reductase as a Risk Factor in Thrombotic Microangiopathies Results From a Pilot Study Clin Appl Thromb Hemost 2009. Vol. 15. P. 283-289
  31. Боброва Л.А., Козловская Н.Л., Шкарупо В.В. и соавт. Влияние генетической формы тромбофилии на клинико-морфологические проявления и характер течения хронического гломерулонефрита. Нефрология и диализ 2010; 1(12): 25-33.
  32. Боброва Л.А., Поражение почек при наследственных и приобретенных тромбофилиях. Автореф. Дисс. Канд.мед.наук., М.2010
  33. Козловская Н.Л., Боброва Л.А., Шкарупо В.В., и соавт. Клинико-морфологические особенности поражения почек у больных с генетической формой тромбофилии. Тер. архив 2009: № 8; с. 30-36
  34. De Serres SA, Isenring P. Athrombocytopenic thrombotic microangiopathy, a condition that could be overlooked based on current diagnostic criteria // Nephrol Dial Transplant 2009. Vol. 24. P.10 48-1050.
  35. Mannucci PM. Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome: much progress and many remaining issues. Haematologica/the Hematology Journal 2007; 92:878-880.
  36. Vessly SK, George JN, Lämmle B et al. ADAMTS-13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients Blood.2003;102:60-68.
  37. Zhou Z, Nguyen TC, Guchhait P, Dong JF. Von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. Semin Thromb Hemost 2010;36(1):71-81.
  38. Tao Z, Anthony K, Peng Y et al. Novel ADAMTS-13 mutations in an adult with delayed onset thrombotic thrombocytopenic purpura. J Thromb Haemost 2006;4(9):1931-1935.
  39. Cao WJ, Niiya M, Zheng XW et al. Inflammatory cytokines inhibit ADAMTS-13 synthesis in hepatic stellate cells and endothelial cells. J Thromb Haemost 2008; 6(7):1233-1235.
  40. Bernardo A, Ball C, Nolasco L et al. Effects of inflammatory cytokines on the release and cleavage of the endothelial cells-derived ultralarge von Willebrand factor multimers under flow. Blood; 2004:104(1):100-106.
  41. Бобкова И.Н., Полянцева Л.Р., Тареева И.Е., Козловская Л.В. Клиническое значение определение фактора Виллебранда у больных волчаночным нефритом. Тер. арх. 1995;67(5):14-16.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies